Corporate Fact Sheet

www.rigel.com • NASDAQ: RIGL

FAST FACTS

Location: South San Francisco, CA

Founded: 1996

2025 Total Revenues[1]: $294M

2025 Net Income[1]: $367M

2025 Cash Balance[2]: $155M

MANAGEMENT TEAM

Raul R. Rodriguez
President & CEO

Dean Schorno, C.P.A.
EVP & Chief Financial Officer

David A. Santos
EVP & Chief Commercial Officer

Alison L. Hannah, M.D.
EVP & Chief Medical Officer

Raymond J. Furey
EVP, General Counsel & Corporate Secretary

Joseph Lasaga
EVP & Chief Business Officer

Julie Patel
SVP, Human Resources

ANALYST COVERAGE

Kristen Kluska
Cantor Fitzgerald & Co.

Yigal Nochomovitz
Citigroup, Inc.

Joseph Pantginis
H.C. Wainwright & Co.

Farzin Haque
Jefferies & Company

Allison Bratzel
Piper Sandler & Co.

1. 2025 total revenues and net income included $40M in non-cash contract revenues related to Rigel's agreement with Eli Lilly (Q2 2025) and 2025 net income included $246M of non-cash deferred income tax benefit (Q4 2025). 2. Cash, cash equivalents & short-term investments as of December 31, 2025. 3. Investigational compound not approved by the FDA.

CORPORATE OVERVIEW

Rigel Pharmaceuticals, Inc. is a commercial stage biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms, which offers the opportunity to help patients who have diseases where few or no approved treatment options exist.

COMMERCIAL PRODUCTS

VEPPANU™ vepdegestrant 200 mg 100 mg	For adults with ER-positive, HER2-negative, *ESR1*-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
Tavalisse® (fostamatinib disodium hexahydrate) tablets	For adult patients with chronic immune thrombocytopenia (ITP), a rare autoimmune disease, who had an insufficient response to a previous treatment.
REZLIDHIA® (olutasidenib) 150 mg capsules	For adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (*IDH1*) mutation.
GAVRETO® pralsetinib 100mg capsules	For adults with metastatic rearranged during transfection (*RET*) fusion-positive non-small cell lung cancer and adults and children 12+ with advanced or metastatic *RET* fusion-positive thyroid cancer.*

ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; ESR1, estrogen receptor 1 gene.
**Thyroid indication is approved on an accelerated approval basis.*

FULL PRESCRIBING INFORMATION

VEPPANU Full Prescribing Information.

TAVALISSE Full Prescribing Information.

REZLIDHIA Full Prescribing Information, including Boxed WARNING.

GAVRETO Full Prescribing Information, including Boxed WARNING.

CLINICAL PROGRAMS

Rigel's wholly-owned clinical pipeline includes R289[3], a potent and selective dual inhibitor of interleukin receptor-associated kinase 1 and 4 (IRAK1/4) with potential in multiple indications. R289 is currently being evaluated in a an open-label Phase 1b study in patients with **lower-risk myelodysplastic syndrome (MDS)** who are relapsed, refractory or resistant to prior therapies. The company anticipates sharing preliminary data from the dose expansion phase of the study by the end of 2026. Rigel is also evaluating potential development opportunities for R289 in additional indications.

Rigel will also evaluate future development opportunities for vepdegestrant.